Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
SciSparc Ltd. - Ordinary Shares
(NQ:
SPRC
)
0.2143
-0.0060 (-2.72%)
Streaming Delayed Price
Updated: 12:56 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about SciSparc Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
September 30, 2024
SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon.
Via
Benzinga
Exposures
Product Safety
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
September 30, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
September 26, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 23, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Why Is SciSparc (SPRC) Stock Up 94% Today?
August 15, 2024
SciSparc stock is up on Thursday with heavy trading of SPRC shares after it provided an update on its merger with AutoMax.
Via
InvestorPlace
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 18, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
September 17, 2024
Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
September 17, 2024
Via
Benzinga
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
September 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
September 11, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
August 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
August 29, 2024
Via
Benzinga
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
August 28, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
August 26, 2024
Via
Benzinga
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
August 23, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
August 22, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients
August 20, 2024
SciSparc Ltd. (NASDAQ: SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at...
Via
Benzinga
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
August 19, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy
August 19, 2024
SciSparc signs an exclusive license agreement with Polyrizon Ltd for its SCI-160 pain treatment program, with potential milestones of $3M in cash plus royalties.
Via
Benzinga
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
August 19, 2024
Via
Benzinga
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
August 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Nasdaq Jumps Over 2%; Walmart Earnings Top Views
August 15, 2024
Via
Benzinga
Dow Surges Over 500 Points; US Retail Sales Rise In July
August 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
August 15, 2024
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news today!
Via
InvestorPlace
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
August 15, 2024
Via
Benzinga
SciSparc Updates Regarding the Status of the AutoMax Merger
August 14, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
August 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
July 22, 2024
From
SciSparc Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.